9995 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$14.76 |
| 52 Week High | HK$37.70 |
| 52 Week Low | HK$10.20 |
| Beta | 0.36 |
| 1 Month Change | -11.83% |
| 3 Month Change | 38.98% |
| 1 Year Change | -55.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9995 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.4% | -3.9% | -0.5% |
| 1Y | -55.6% | -5.7% | 19.9% |
Return vs Industry: 9995 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 9995 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 9995 volatility | |
|---|---|
| 9995 Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9995's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9995's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,497 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
RemeGen Co., Ltd. Fundamentals Summary
| 9995 fundamental statistics | |
|---|---|
| Market cap | HK$14.76b |
| Earnings (TTM) | -HK$1.65b |
| Revenue (TTM) | HK$1.62b |
4.9x
P/S Ratio-4.8x
P/E RatioIs 9995 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9995 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.52b |
| Cost of Revenue | CN¥324.22m |
| Gross Profit | CN¥1.20b |
| Other Expenses | CN¥2.75b |
| Earnings | -CN¥1.55b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.89 |
| Gross Margin | 78.70% |
| Net Profit Margin | -101.95% |
| Debt/Equity Ratio | 105.0% |
How did 9995 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RemeGen Co., Ltd. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Shun Kei Law | CCB International Securities Limited |